Imunon, Inc. Advances Phase 3 Trial for Innovative Cancer Treatment

Imunon, Inc. ((IMNN)) announced an update on their ongoing clinical study.

Imunon, Inc. is conducting a Phase 3 clinical trial titled A Randomized Phase 3 Trial Evaluating the Safety & Efficacy of IP IMNN-001 Administered in Combination w/ Standard Neoadjuvant & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer. The study aims to assess the safety and efficacy of the drug IMNN-001 when used alongside standard chemotherapy in patients with advanced ovarian, fallopian tube, or primary peritoneal cancer. This trial is significant as it explores potential improvements in treatment outcomes for these conditions.

The intervention being tested is IMNN-001, an IL-12 plasmid formulated with PEG-PEI-Cholesterol Lipopolymer, administered intraperitoneally. It is designed to enhance the efficacy of standard chemotherapy regimens, which include drugs like Paclitaxel and Carboplatin.

The study follows a randomized, parallel assignment model without masking, focusing primarily on treatment. Participants are randomly assigned to receive either the experimental treatment with IMNN-001 and standard chemotherapy or standard chemotherapy alone.

The trial began on July 9, 2025, with the most recent update submitted on August 12, 2025. These dates are crucial for tracking the study’s progress and ensuring timely updates for stakeholders and potential participants.

The market implications of this study are significant for Imunon, Inc. A successful outcome could enhance the company’s stock performance and attract investor interest, especially given the competitive landscape in oncology treatments. This trial could position Imunon as a leader in innovative cancer therapies.

The study is currently ongoing, with further details available on the ClinicalTrials portal.